⌕
Geron · GERN · Nasdaq
Tenet 55 · Mixed
Compare
$1.00+6.17%At closeTenet 55 · Mixed
$1.00+0.06 (+6.17%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Geron (GERN) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

The percentage on each card is GERN's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

● MarketBeatNov 10, 2026 · 23:14 ET
Geron Targets Germany Launch and Deals as RYTELO Sales Grow

Geron NASDAQ: GERN is focusing on expanding U.S. use of its blood cancer drug RYTELO, preparing for a commercial sale in Germany and evaluating potential deals after discontinuing a late-stage trial in another indication…

GERN +6.2% todayRead at source ↗
● Defense WorldNov 6, 2026 · 02:29 ET
Geron (NASDAQ:GERN) & MDxHealth (NASDAQ:MDXH) Critical Review

Geron (NASDAQ: GERN - Get Free Report) and MDxHealth (NASDAQ: MDXH - Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the streng…

GERN +6.2% todayRead at source ↗
● The Motley FoolNov 5, 2026 · 06:54 ET
Geron: 3 Key Takeaways for Long-Term Investors

RYTELO quarterly net product revenue rose 27% year over year. Geron discontinued its Phase III trial in relapsed myelofibrosis.…

GERN +6.2% todayRead at source ↗
● MarketBeatNov 4, 2026 · 12:14 ET
Geron Q3 Earnings Call Highlights

Geron NASDAQ: GERN reported third-quarter net product revenue of $60.1 million for RYTELO, a 27% increase from $47.2 million a year earlier, as the company cited continued growth in prescribing, particularly among commun…

GERN +6.2% todayRead at source ↗
● Seeking AlphaNov 4, 2026 · 11:04 ET
Geron Corporation (GERN) Q3 2026 Earnings Call Transcript

Geron Corporation (GERN) Q3 2026 Earnings Call Transcript…

GERN +6.2% todayRead at source ↗
● Zacks Investment ResearchNov 4, 2026 · 09:56 ET
Geron (GERN) Reports Break-Even Earnings for Q3

Geron (GERN) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.01. This compares to a loss of $0.03 per share a year ago.…

GERN +6.2% todayRead at source ↗
● GlobeNewsWireNov 4, 2026 · 09:00 ETCOMPANY'S OWN WORDS
Geron Corporation to Present Data Highlighting Clinical and Biological Activity of RYTELO® (imetelstat) at ASH 2026

FOSTER CITY, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a hematology-focused commercial stage biopharmaceutical company pursuing more meaningful moments for people living with blood cance…

GERN +6.2% todayRead at source ↗
● GlobeNewsWireNov 4, 2026 · 07:03 ETCOMPANY'S OWN WORDS
Geron Corporation Reports Third Quarter 2026 Financial Results and Recent Business Highlights

Achieved $60.1 million in RYTELO ® (imetelstat) net product revenue in Q3 2026, an increase of 5% compared to Q2 2026…

GERN +6.2% todayRead at source ↗
● GlobeNewsWireNov 3, 2026 · 08:00 ETCOMPANY'S OWN WORDS
Geron Corporation to Participate in the Stifel 2026 Healthcare Conference

FOSTER CITY, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a hematology-focused biopharmaceutical company pursuing more meaningful moments for people living with blood cancer, today announce…

GERN +6.2% todayRead at source ↗
● Seeking AlphaNov 2, 2026 · 08:15 ET
Geron: Opportunity Builds Even As Struggles Continue

Geron achieved FDA approval for RYTELO (imetelstat) in June 2024, targeting lower-risk myelodysplastic syndromes (LR-MDS). RYTELO is Geron's only advanced-stage asset, marking a pivotal milestone. GERN's recent pullback …

GERN +6.2% todayRead at source ↗
● Defense WorldNov 2, 2026 · 06:03 ET
Geron (GERN) Expected to Announce Earnings on Wednesday

Geron (NASDAQ: GERN - Get Free Report) is expected to post its Q3 2026 results before the market opens on Wednesday, November 4th. Analysts expect Geron to post earnings of ($0.01) per share and revenue of $60.36 million…

GERN +6.2% todayRead at source ↗
● BenzingaOct 28, 2026 · 13:55 ET
Penny Stock Geron Ends Advanced Cancer Study, Shifts Focus to Commercial Growth

Geron Corporation (NASDAQ:GERN) shares plunged on Wednesday after the company halted its late-stage cancer program.…

GERN +6.2% todayRead at source ↗
● ReutersOct 28, 2026 · 08:15 ET
Geron discontinues late-stage trial of blood cancer drug

Geron said on ‌Wednesday it would discontinue a late-stage trial testing its treatment for ​patients with a form ​of rare blood cancer.…

GERN +6.2% todayRead at source ↗
● GlobeNewsWireOct 28, 2026 · 08:00 ETCOMPANY'S OWN WORDS
Geron Corporation Provides Update on Phase 3 IMpactMF Clinical Trial of Imetelstat in Relapsed/Refractory Myelofibrosis

FOSTER CITY, Calif., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage hematology biopharmaceutical company, today announced the decision to discontinue the Phase 3 IMpactMF trial eva…

GERN +6.2% todayRead at source ↗
● GlobeNewsWireOct 21, 2026 · 08:00 ETCOMPANY'S OWN WORDS
Geron Plans to Announce Third Quarter 2026 Financial Results on November 4, 2026

FOSTER CITY, Calif., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a hematology-focused biopharmaceutical company pursuing more meaningful moments for people living with blood cancer, today announce…

GERN +6.2% todayRead at source ↗
● GlobeNewsWireOct 19, 2026 · 16:01 ETCOMPANY'S OWN WORDS
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

FOSTER CITY, Calif., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a hematology-focused biopharmaceutical company pursuing more meaningful moments for people living with blood cancer, today reported…

GERN +6.2% todayRead at source ↗
● PRNewsWireOct 13, 2026 · 14:52 ET
Did Geron Corporation Insiders Breach their Fiduciary Duties to Shareholders?

Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket p…

GERN +6.2% todayRead at source ↗
● Business WireOct 12, 2026 · 12:14 ETCOMPANY'S OWN WORDS
Geron Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Geron Corporation - GERN

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation in…

GERN +6.2% todayRead at source ↗
● Globe News WireOct 12, 2026 · 08:03 ET
Geron Corporation Announces Oral Presentations Highlighting Imetelstat at International Hematology Congresses in Europe and Asia

Presentations feature real-world experience and clinical evidence in lower-risk MDS, underscoring growing global scientific engagement with imetelstat FOSTER CITY, Calif. , Oct. 12, 2026 (GLOBE NEWSWIRE) -- Geron Corpora…

GERN +6.2% todayRead at source ↗
● PRNewsWireSep 25, 2026 · 22:35 ET
Did Geron Corporation Insiders Breach their Fiduciary Duties to Shareholders?

Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket p…

GERN +6.2% todayRead at source ↗
● PRNewsWireSep 25, 2026 · 22:00 ETCOMPANY'S OWN WORDS
Geron Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Geron Corporation - GERN

NEW YORK and NEW ORLEANS, Sept. 25, 2026 /PRNewswire/ -- Former Attorney General of Louisiana, Charles C.…

GERN +6.2% todayRead at source ↗
● GlobeNewsWireSep 18, 2026 · 16:01 ET
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

FOSTER CITY, Calif., Sept. 18, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a hematology-focused biopharmaceutical company pursuing more meaningful moments for people living with blood cancer, today reporte…

GERN +6.2% todayRead at source ↗
● MarketBeatSep 16, 2026 · 09:03 ET
Geron Eyes High End of 2026 RYTELO Revenue Guidance as Community Adoption Expands

Geron NASDAQ: GERN executives said the company remains on track to generate 2026 RYTELO net revenue of $220 million to $240 million, with Chief Executive Officer Harout Semerjian saying the company now expects results to…

GERN +6.2% todayRead at source ↗

Kept in their own lane. A press release is the company talking, not reporting.

No upcoming events in the feeds.

NVDA31−0.4%
WDAY4−5.8%
BBW3−2.6%

Article counts from the last market-wide feed page, across every symbol we track and not just GERN · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.